We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
-$43.5M
Cap. Flow
+$1.54M
Cap. Flow %
0.14%
Top 10 Hldgs %
61.62%
Holding
73
New
4
Increased
21
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$37.9M
2
INSP icon
Inspire Medical Systems
INSP
+$25.6M
3
IMGN
Immunogen Inc
IMGN
+$14.9M
4
RVTY icon
Revvity
RVTY
+$14.5M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$12.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.8M
2
DHR icon
Danaher
DHR
+$16.2M
3
NTRA icon
Natera
NTRA
+$12M
4
AMRX icon
Amneal Pharmaceuticals
AMRX
+$11.2M
5
GSK icon
GSK
GSK
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.59%
2 Miscellaneous 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZIMV
26
DELISTED
ZimVie
ZIMV
$9.7M 0.85%
+546,444
New +$5.51M
DHR icon
27
Danaher
DHR
$152B
$9.49M 0.83%
41,041
-76,027
-65% -$16.2M
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$2.51B
$9.16M 0.8%
1,529,047
-950,056
-38% -$5.51M
WAT icon
29
Waters Corp
WAT
$40.7B
$9.13M 0.8%
27,719
+4,595
+20% +$1.27M
LQDA icon
30
Liquidia Corp
LQDA
$6.06B
$8.29M 0.73%
688,926
-706,528
-51% -$5.09M
PBYI icon
31
Puma Biotechnology
PBYI
$468M
$7.34M 0.64%
1,695,021
+13,872
+0.8% +$46K
CNC icon
32
Centene
CNC
$32B
$7.21M 0.63%
97,198
-93,409
-49% -$6.74M
ELV icon
33
Elevance Health
ELV
$85.5B
$7.12M 0.63%
15,094
-6,600
-30% -$3.05M
TSHA icon
34
Taysha Gene Therapies
TSHA
$1.88B
$6.69M 0.59%
3,780,714
+2,074,940
+122% +$4.14M
GOSS icon
35
Gossamer Bio
GOSS
$83.2M
$5.87M 0.52%
6,432,715
+2,004,858
+45% +$1.48M
AMRN
36
Amarin Corp
AMRN
$295M
$5.3M 0.47%
304,775
-116,819
-28% -$1.83M
A icon
37
Agilent Technologies
A
$43.4B
$5.26M 0.46%
37,854
-3,971
-9% -$472K
TSVT
38
DELISTED
2seventy bio
TSVT
$4.86M 0.43%
1,139,111
-314,267
-22% -$966K
IMVT icon
39
Immunovant
IMVT
$8.51B
$4.79M 0.42%
+113,793
New +$4.19M
STRO icon
40
Sutro Biopharma
STRO
$339M
$4.53M 0.4%
105,646
+28,682
+37% +$910K
ICLR icon
41
Icon
ICLR
$13.1B
$4.36M 0.38%
15,417
-5,581
-27% -$1.44M
NAMS icon
42
NewAmsterdam Pharma
NAMS
$3.1B
$4.18M 0.37%
374,404
-286,214
-43% -$2.62M
MRUS
43
DELISTED
Merus
MRUS
$3.18M 0.28%
115,726
-18,284
-14% -$427K
VRDN icon
44
Viridian Therapeutics
VRDN
$2.61B
$2.99M 0.26%
137,343
-305,927
-69% -$4.83M
AVTR icon
45
Avantor
AVTR
$9.86B
$2.88M 0.25%
125,964
+41,469
+49% +$850K
BHVN icon
46
Biohaven
BHVN
$2.33B
$2.86M 0.25%
66,898
-64,205
-49% -$2M
IQV icon
47
IQVIA
IQV
$43.1B
$2.84M 0.25%
12,263
-10,778
-47% -$2.21M
MCRB icon
48
Seres Therapeutics
MCRB
$51.3M
$2.45M 0.22%
87,677
-29,951
-25% -$786K
MOH icon
49
Molina Healthcare
MOH
$10.4B
$2.21M 0.19%
6,117
-6,117
-50% -$2.16M
IFRX icon
50
InflaRx
IFRX
$329M
$2.13M 0.19%
1,305,140
-432,404
-25% -$741K
1
2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Eversept Partners held 73 positions worth $1.14B, down 3.7% from $1.18B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Eversept Partners's Q4 2023 filing shows 4 new, 21 increased, 29 reduced and 16 closed positions. Its largest new stake was Immunogen Inc: 748,950 shares worth $22.2M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

  • Eversept Partners's largest Q4 2023 buy was Immunogen Inc: 748,950 shares worth $22.2M.
  • Eversept Partners added most to argenx in Q4 2023, an estimated $37.9M increase.
  • Eversept Partners's biggest Q4 2023 reduction was Danaher, cutting an estimated $16.2M.
  • Eversept Partners fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $23.8M.
  • Eversept Partners's ten largest holdings make up 62% of its $1.14B portfolio in Q4 2023.
  • Eversept Partners opened 4 new positions and closed 16 in Q4 2023.
  • Eversept Partners's portfolio value fell 3.7% quarter-over-quarter to $1.14B.

Based on Eversept Partners's 13F filing for Q4 2023, filed 14 Feb 2024.